Investigator-initiated multi-institutional phase I clinical trial of NY-ESO-1-specific TCR gene-modified T cell therapy for adult T cell leukemia/lymphoma patients relapsed after allogeneic hematopoietic stem cell transplantation
Latest Information Update: 11 Jan 2022
Price :
$35 *
At a glance
- Drugs Mipetresgene autoleucel (Primary) ; Cyclophosphamide
- Indications Adult T-cell leukaemia-lymphoma
- Focus Adverse reactions
- 08 Oct 2021 Planned End Date changed from 31 Mar 2021 to 31 Jan 2021.
- 26 Feb 2021 Status changed from active, no longer recruiting to discontinued.
- 26 Jun 2020 Status changed from recruiting to active, no longer recruiting.